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Critical Evaluation of Natriuretic Peptide Testing in Heart FailureABSTRACTCirculating natriuretic peptide measurements have been used extensively over the past 15 years to diagnose and monitor
patients with heart failure. We are still learning how complex the dynamics of natriuretic peptides can be in the inter-
pretation of test results in individual patients. Although natriuretic peptide measurements are widely used in practice,
there are questions regarding why these peptides may not necessarily track with blood volume or invasive hemodynamic
measurements in individual patients. Interpretation of natriuretic peptide measurements will depend on many factors,
including special patient populations, obesity, renal function, the state of congestion or decongestion, and whether
patients are receiving speciﬁc therapies. Natriuretic peptide measurements have clearly revolutionized clinical care
for patients with heart failure, but further research should provide insights to help use these measurements to individ-
ualize patient care beyond the current guidelines. (J Am Coll Cardiol 2016;67:330–7) © 2016 by the American College of
Cardiology Foundation.T he ﬁrst measurements of circulating atrialnatriuretic peptide (ANP) in patients oc-curred in the early 1980s (1). Burnett et al.
(1) from the Mayo Clinic measured circulating ANP
in human volunteers and patients with various car-
diovascular diseases, including heart failure (HF).
These measurements built on previous work of de
Bold et al. (2), who reported that injecting atrial
myocardial extracts intravenously into rats produced
a rapid and potent natriuretic response. Burnett et al.
(3) had previously reported a decrease in blood pres-
sure and inhibition of the renin-angiotensin-
aldosterone system with injection of synthetic ANP
into animals, but it was their later seminal clinical
research work that introduced us to the concept of a
circulating biochemical marker as a means to “diag-
nose” increased ﬁlling pressure in patients with heart
disease. Original studies by Troughton et al. (4),
Maisel et al. (5), Januzzi et al. (6), and others trans-
lated these early observations into clinical practice
by demonstrating that natriuretic peptides are
extremely useful in the diagnosis of HF, essentially
changing the clinical approach to the care of the
patient with HF.
The idea of measuring a circulating biomarker to
measure the presence and severity of HF was on its
way to what has become an interesting journey.
Moving forward from the early 1980s to the present
time, when natriuretic peptides (primarily B-type
natriuretic peptide [BNP] and its inactive fragment,
N-terminal pro–B-type natriuretic peptide [NT-
proBNP]) are widely used to aid clinical decision
making in patients with HF, sets the stage for a crit-
ical appraisal of where we are today with thesebiomarkers. It raises the question of whether we are
really better off today with the publication of the
seminal Burnett et al. (1) paper in Science than we
were in 1986. How should we now use and apply
these biomarkers today in the care of our patients
with shortness of breath and/or HF?
We now know much more about ANP, BNP, and
NT-proBNP than before. At present, biologically
inactive NT-proBNP and BNP are the most widely-
used diagnostic biomarker tools for the evaluation of
patients with dyspnea and/or HF. Careful clinical
evaluation/reasoning and interpretation of the
biomarker in the correct context will always trump a
biomarker test alone in patients with the complex
syndrome of HF. Clinical decision making is a craft
involving numerous factors, including experience and
an understanding of scientiﬁc evidence. It must be
ﬁne-tuned when dealing with individual patients, and
should be tailored to speciﬁc clinic settings (such as
the emergency department), or to special patient
populations (e.g., those with renal dysfunction). The
measurement of any biomarker in isolation, without
clinical context, will never be acceptable. Never-
theless, natriuretic peptide measurements are readily
available and widely used, but still do not always
provide clear-cut guidance regarding speciﬁc
therapies.
WHAT ARE NATRIURETIC PEPTIDES?
The late 1980s and early 1990s produced a huge
amount of literature on natriuretic peptides. Marked
elevation of cardiac ﬁlling pressure, with or without
the syndrome of HF, is clearly accompanied by higher
TABLE 1 Current Indications for Na
Indication
Diagnosis in patients with dyspnea (ac
Diagnosis in patients with dyspnea (am
Prognosis in patients with known HF (
Prognosis in patients with known HF (
Achieving guideline-directed medical t
Natriuretic peptide-guided therapy for
Class I: conditions for which there is evidence
useful and effective; Class IIa: weight of evide
efﬁcacy is less well established by evidence
evidence frommultiple randomized trials or m
evidence from a single randomized trial or no
ACC/AHA ¼ American College of Cardiolog
ABBR EV I A T I ON S
AND ACRONYMS
ACC/AHA = American College of
Cardiology/American Heart
Association
ANP = atrial natriuretic peptide
BNP = B-type natriuretic peptide
HF = heart failure
NT-proBNP = N-terminal pro–B-
type natriuretic peptide
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peptides. BNP is produced as a pre-
prohormone, then processed to proBNP,
which is cleaved by corin to produce bio-
logically active BNP and inactive NT-
proBNP. BNP (but not NT-proBNP) is one
of many substrates degraded by neprilysin
(a fact that has recently increased in
clinical relevance with the results of
PARADIGM-HF [Prospective Comparison
of Angiotensin Receptor-Neprilysin In-hibitor with Angiotensin-Converting-Enzyme Inhibi-
tor to Determine Impact on Global Mortality and
Morbidity in Heart Failure Trial]; see later discussion
of wet and dry natriuretic peptide levels).
With clinical experience, it soon became clear that
sodium retention and peripheral edema still occur in
patients with HF, despite elevated circulating natri-
uretic peptide levels. This seemed paradoxical, as
high-circulating natriuretic peptide levels were
thought to counteract the syndrome of HF. Circu-
lating natriuretic peptide assay levels may include a
mix of NT-proBNP, BNP fragments, ANP, and C-type
natriuretic peptide. Some of these may be less bio-
logically active than BNP. We knew that ANP was
located in the speciﬁc cardiac myocyte granules ﬁrst
described by Jamieson and Palade in 1964 (7). These
are membrane-bound, polypeptide-hormone-storing
granules, 250 to 500 mm in diameter. ANP and BNP are
often found coexisting in the same storage granule. It
is not clear why some BNP is stored in a processed
form, whereas ANP is stored mainly unprocessed. In
general, BNP shares a similar biological spectrum of
activity with ANP. Under certain conditions where
there may be continuous stimulation of natriuretic
peptides (as may occur in severe HF), there may be
differences in the production of these hormones.
Both ANP and BNP receptors activate guanylatetriuretic Peptide Measurements in HF
ACC/AHA Recommendation
Class-Level of Evidence
ute) I-A
bulatory) I-A
acute) I-A
ambulatory) I-A
herapy (ambulatory) IIa-B
chronic HF IIb-B
and/or general agreement that a given procedure or treatment is
nce/opinion is in favor of usefulness/efﬁcacy; Class IIb: usefulness/
/opinion. Level of Evidence: A: recommendation on the basis of
eta-analyses; Level of Evidence; B: recommendation on the basis of
nrandomized studies.
y/American Heart Association; HF ¼ heart failure.cyclase to generate cyclic guanosine monophosphate,
which results in vasodilation. The C-receptor, some-
times referred to as the natriuretic peptide clearance
receptor, probably signals through G-proteins, rather
than cyclic guanosine monophosphate. Natriuretic
peptides also interact with adrenal glomerulosa,
where they reduce aldosterone production via a
change in ion channel activity. Both the synthesis and
the release of aldosterone are inhibited by natriuretic
peptides. The sympathetic nervous system is also
inhibited by natriuretic peptides. ANP reduces renin
secretion and arginine vasopressin secretion. Both
ANP and BNP inhibit release of endothelin-1 from
endothelial cells. Both have antigrowth properties
in the vasculature. A recent review described the
current use of natriuretic peptides in the syndrome
of HF (8).
CONTROL OF NATRIURETIC PEPTIDE
RELEASE
ANP and BNP are both continuously released from the
heart. Atrial muscle stretch is well known to augment
ANP and BNP release, although the precise mecha-
nism is unknown. Nevertheless, heightened release
of ANP and BNP is a direct consequence of mechanical
stretch of atrial muscle (9). It may be that increases in
atrial dimension, rather than changes in atrial pres-
sure, stimulate natriuretic peptide release (9). This
concept is supported by the observation that in pa-
tients with cardiac tamponade, the high pressure, but
low volume in the atria is associated with low-normal
ANP levels, whereas pericardiocentesis results in
elevated ANP (10). ANP is also elevated in patients
with ongoing supraventricular tachycardia and atrial
ﬁbrillation in the absence of HF.
ANP is released mainly from the atria. ANP
messenger ribonucleic acid reaches only modest
ventricular levels (7%), relative to atrial levels (11).
Unlike ANP, BNP resides primarily in ventricular
muscle. BNP messenger ribonucleic acid content is
much higher in the ventricle. BNP is cleared more
slowly from the circulation than ANP. BNP release is
also stimulated by endothelin-1 and phenylephrine.
BNP and NT-proBNP are mainly products of the ven-
tricular myocytes. Most hospitals now use NT-proBNP
or BNP assays to measure natriuretic hormone levels.
Asian and Black patients with HF have higher natri-
uretic peptide levels on admission compared with
White and Hispanic patients (12). Patients with severe
HF have markedly increased myocardial tissue con-
centrations of ANP that parallel the increased circu-
lating levels (13). Obese patients tend to have low
circulating natriuretic peptide levels for a given
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333degree of HF (14), and these ﬁndings are not driven by
enhanced BNP clearance mediated by natriuretic
peptide clearance receptors (15).
CURRENT USES OF NATRIURETIC PEPTIDES
A large body of evidence supports the use of the
natriuretic peptides (both BNP and NT-proBNP) for
the evaluation and management of patients with
HF in a variety of clinical settings. Table 1 shows
current indications for natriuretic peptide mea-
surements in HF from the American College of
Cardiology/American Heart Association (ACC/AHA)
guidelines (16). The use of natriuretic peptides in
risk stratiﬁcation has been studied in other clinical
settings, such as in acute coronary syndromes, atrial
ﬁbrillation, and valvular heart disease. However,
there is insufﬁcient evidence to date for a strong
recommendation for natriuretic peptide testing in
any of these disease states, and none have Level 1
recommendations in the relevant clinical practice
guidelines. The evidence supporting speciﬁc clinical
uses of natriuretic peptides in HF is brieﬂy dis-
cussed later.
DIAGNOSIS IN PATIENTS WITH
UNCLEAR SYMPTOMS
The diagnosis of HF in patients presenting with dys-
pnea in either urgent care or ambulatory settings is
among the strongest indications for natriuretic peptide
testing, with a Class I/Level of Evidence: A recom-
mendation in the ACC/AHA guidelines. In the urgent
care/emergency setting, the landmark Breathing Not
Properly trial evaluated 1,586 patients presenting to
the emergency department with unexplained breath-
lessness, and demonstrated that a BNP threshold
of 100 pg/ml could distinguish between a diagnosis
of HF and other causes of dyspnea with a high degree
of accuracy (area under the receiver-operating char-
acteristic curve: 0.91) (5). In particular, the negative
predictive value of BNP <100 pg/ml was high, sug-
gesting that such patients had a very low likelihood of
having acute HF as an explanation for their symptoms.
Similar data with NT-proBNP from the PRIDE (ProBNP
Investigation of Dyspnea) study support the accuracy
of NT-proBNP for diagnosis in this same setting (6),
although speciﬁc age-related thresholds (NT-proBNP
>450 pg/ml for patients <50 years of age and NT-
proBNP >900 pg/ml for patients 50 years of age or
older) have been proposed for NT-proBNP, rather than
a single cutpoint. As with all diagnostic tests, inter-
pretation of the results must take into account impor-
tant sources of false negatives (e.g., obesity), other
conditions that may elevate natriuretic peptide levels(e.g., aging and chronic kidney disease), and alter-
native diagnoses (e.g., acute coronary syndrome or
pulmonary embolus). In the setting of “grey zone,”
natriuretic peptide values (i.e., intermediate be-
tween the optimized threshold to exclude HF and
the optimized threshold to deﬁnitively diagnose it),
other ancillary clinical information and knowledge
of prior natriuretic peptide values may be extremely
helpful.
Both BNP and NT-proBNP have also been evaluated
for use in the outpatient setting in establishing the
diagnosis of HF. Importantly, because patients in the
ambulatory setting are typically less symptomatic
and are less hemodynamically decompensated, diag-
nostic thresholds are generally lower to avoid false
negative results. As with diagnosis of HF in the acute
setting, published data suggest a single threshold for
BNP, but age adjustment for NT-proBNP. A staged
approach to ambulatory patients with suspicion of HF
using initial natriuretic peptide screening, followed
by echocardiography in patients with elevated values,
is supported by the most recent European Society of
Cardiology guidelines (17).
ESTIMATING PROGNOSIS IN PATIENTS
WITH KNOWN HF
The natriuretic peptides are among the most powerful
prognostic markers in all forms of clinical HF,
including HF with reduced ejection fraction (18),
HF with preserved ejection fraction (19), and acute HF
(20). In the chronic setting, some of the most
compelling data come from the extensive analysis of
the Val-HeFT database, where both baseline values
and changes over 3 months in BNP and NT-proBNP
have been shown to be among the most powerful
predictors of future outcomes (21). Similarly, in the
acute setting, both elevations of the initial value at
the time of presentation (20) and changes with ther-
apy (or value at hospital discharge) are strong pre-
dictors of short- (22) and long-term outcomes (23).
Although establishing prognosis may be useful for
risk stratiﬁcation, estimating risk alone is of marginal
clinical value unless it affects the actual delivery of
care in a meaningful way. There has therefore been
substantial interest in the concept of titrating or
“guiding” clinical care using natriuretic peptide
values, so-called biomarker-guided therapy.
NATRIURETIC PEPTIDE–GUIDED THERAPY
The concept of guiding chronic care on the basis of
levels of a biomarker is common in many chronic
diseases, such as diabetes, hypertension, and hepa-
titis C. The concept of adjusting chronic HF therapy to
CENTRAL ILLUSTRATION Natriuretic Peptide Testing in Heart Failure: The Inﬂuence of Neprilysin Inhibitors
Francis, G.S. et al. J Am Coll Cardiol. 2016; 67(3):330–7.
The use of LCZ696 (sacubitril/valsartan, also known as Entresto) will likely inﬂuence circulating natriuretic peptide levels in patients with heart failure.
Because B-type natriuretic peptide (BNP), but not N-terminal pro–B-type natriuretic peptide (NT-proBNP), is a substrate of neprilysin, levels of circulating
BNP may reﬂect the action of the drug. BNP levels may rise in patients taking sacubritil/valsartan due to neprilysin inhibition. However, circulating
NT-proBNP levels may fall due to diminished left atrial and left ventricular wall stress.
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tested in a variety of small clinical trials, with varying
designs and results, and was recently reviewed (24).
Although pooled analyses of these studies indicate a
20% to 25% reduction in mortality with biomarker-
guided therapy, generalizability has been limited by
the small size of the studies, as well as signiﬁcant
heterogeneity in the inclusion criteria, treatment
strategies, natriuretic peptide cutpoints, and results
(25,26). In light of this uncertainty, current guidelines
do not recommend the use of serial natriuretic pep-
tide measurements to guide titration of therapy in
chronic HF, and a larger National Institutes of Health
trial testing this concept is ongoing (27). It isimportant to recognize that knowledge of incremen-
tal prognostic value may not guarantee the feasibility
or ultimate beneﬁt of intensifying drug therapy ac-
cording to speciﬁc biomarker targets.
In addition to guiding therapy of patients with
known HF, there is increasing interest in using
natriuretic peptide measurements to target at-risk
populations without clinical HF for prevention
strategies. Two recent randomized clinical trials,
PONTIAC (NT-proBNP Guide of Primary Prevention of
Cardiovascular Events in Diabetic Patients) (28) and
STOP-HF (Screening to Prevent Heart Failure) (29),
have demonstrated improvements in clinical out-
comes with a strategy of using natriuretic peptide to
J A C C V O L . 6 7 , N O . 3 , 2 0 1 6 Francis et al.
J A N U A R Y 2 6 , 2 0 1 6 : 3 3 0 – 7 Evaluation of BNP as a Test in HF
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prevention strategies. Whether and how these
promising initial results can be implemented on a
broader population level is an area of active ongoing
research.
REFINEMENTS OF CLINICAL
NATRIURETIC PEPTIDE TESTING
When natriuretic peptide testing was ﬁrst introduced
for clinical use more than 15 years ago, it was reas-
suring that levels were invariably elevated in most
settings of HF (especially during exacerbations) and
often tracked with clinical stability. However, clini-
cians also realized that levels may vary widely among
patients with the same degree of symptoms or echo-
cardiographic parameters, which requires occasional
adjustments to individualize clinical interpretation.
For example, almost a quarter of patients with
chronic symptomatic HF may have natriuretic pep-
tide levels in the lower ranges (30), and their levels
should be explained by other contributing factors
(e.g., obesity, ischemia) when clinical presentation is
out of proportion to their degree of disease severity
by other measures. In contrast, euvolemic patients
(particularly older women, likely with lower lean
mass) may have higher ranges (13). Meanwhile,
natriuretic peptide levels are consistently higher in
patients with underlying chronic kidney disease. As
patients reach end-stage renal disease, natriuretic
peptide levels can be 10-fold higher than the opera-
tional range common to non–end-stage renal disease
patients (31). Yet, in those undergoing hemodialysis,
natriuretic peptides may not track tightly with vol-
ume excess or insufﬁcient clearance, but an increase
over time still portends poor prognosis (32). Taken
together, tracking individual patients’ own natri-
uretic peptide trajectories seems to be the prevailing
clinical strategy, integrating the results by accounting
for different factors (33). It should be emphasized that
patients with an elevated natriuretic peptide level,
even in the absence of ongoing acute symptoms, have
a poor prognosis.
Analytical variability has long been an issue with
point-of-care BNP testing, and may differ from lot to
lot. Laboratory-based testing has improved this
variability, but different antibodies used by different
assays from different vendors may affect diagno-
stic ranges and are often difﬁcult to harmonize.
Furthermore, the intrinsic biological variability
appeared signiﬁcant for serial measurements of both
BNP and NT-proBNP—up to 130% reported in one
study (34). This clearly can have an impact on the
overall accuracy of the results.“WET” AND “DRY”
NATRIURETIC PEPTIDE LEVELS
The rise in natriuretic peptide levels was originally
explained by an acute increase in myocardial stretch,
leading to transcriptomic expression and rapid in-
duction of the counter-regulatory machinery to
maintain homeostasis. However, over time, more
constitutively produced (“dry”) natriuretic peptides
appear, and congestion-driven (“wet”) natriuretic
peptide levels often comprise a portion of the
total quantity of detectable natriuretic peptide
levels. This may explain why, in the advanced
HF setting, changes in natriuretic peptides may not
necessarily track with blood volume or invasive he-
modynamic measurements, both cross-sectionally
and over time (35). Therefore, any rise in natri-
uretic peptide levels requires careful interpretation
in clinical context, as intensifying medical therapy
cannot relieve all factors affecting natriuretic
peptide levels. Unexplained and persistent rises in
natriuretic peptide levels may warrant thorough in-
vestigations (e.g., occult arrhythmias, dietary indis-
cretion, systemic diseases [e.g., thyroid dysfunction
or cancer]).
This intricate balance between wet and dry natri-
uretic peptides is further illustrated by changes in
natriuretic peptide levels following initiation of drug
therapies. For example, early initiation of anti-
adrenergic blockers may paradoxically raise natri-
uretic peptide levels (36), whereas long-term beneﬁts
of antiadrenergic therapy may track with overall
reduction in natriuretic peptide levels over time (37).
More recently, in the PARADIGM-HF trial, adminis-
tration of sacubitril/valsartan has been noted to block
neprilysin’s ability to degrade endogenous BNP, thus
leading to an overall increase in BNP, yet its beneﬁcial
effects resulted in a reduction in NT-proBNP levels
(38) (Central Illustration). There has been a recent
suggestion that angiotensin receptor-neprilysin in-
hibitor may alter glycosylation and deglycosylation of
NT-proBNP, but the precise role that this plays in the
interpretation of natriuretic peptide levels for pa-
tients taking sacubitril/valsartan is speculative (39).
These observations highlight the importance of tak-
ing the biological underpinnings of the disease and its
treatment effects into account when interpreting
natriuretic peptide levels.
NATRIURETIC PEPTIDE TESTING IN ACUTE HF
Beyond its diagnostic role, the usefulness of natri-
uretic peptide–guided therapy for acutely decom-
pensated HF is less well established (16). In fact,
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BNP, in part due to the relatively longer half-life of
NT-proBNP, which may not equilibrate to steady-
state levels until up to 1 week after clinical stabiliza-
tion. Transient ﬂuctuations in renal functions, as a
result of decongestive and vasoactive therapies dur-
ing decompensated states, may also inﬂuence renal
clearance of natriuretic peptides. This common
“rebound” scenario, observed in some cases after the
initial aggressive diuresis phase, results in ﬂuctuating
renal volume status in the transition to clinical sta-
bility (40). Hence, the lack of immediate reductions in
natriuretic peptides following decongestion should
not necessarily concern clinicians and their patients.
Yet, because lower levels often track with better
outcomes, further investigations are warranted if
levels become persistently elevated.
On the contrary, clinicians often ignore the
critical period during HF hospitalizations where risk
stratiﬁcation can be crucial in planning for post-
discharge care. Although the >30% reduction in
natriuretic peptide levels has been considered an
unofﬁcial therapeutic goal, it appears that the overall
ranges of natriuretic peptide elevation (especially in
the chronic setting [i.e., “dry” natriuretic peptide])
may provide more prognostic value than acute
changes. In other words, the persistence of high
(>5,000 pg/ml) NT-proBNP levels long after decon-
gestion portends poor outcomes, regardless of rela-
tive changes. This point is often overlooked, but is
clearly illustrated in the post-hoc analysis of the
PROTECT (ProBNP Outpatient Tailored Chronic Heart
Failure Trial) trial (41). It points to the important roleof natriuretic peptide testing for risk stratiﬁcation,
not only in terms of predicting rehospitalization or
mortality, but in the management of patient expec-
tations, including advanced therapeutics or end-of-
life care considerations. It is reasonable to measure
natriuretic peptide levels at the time a patient is
admitted to the hospital for HF and during an early
outpatient follow-up visit.
CONCLUSIONS
There is little debate that natriuretic peptide testing
has revolutionized clinical care for patients with HF
over the past decade. The measurement of natriuretic
peptides can help us to gain insights into the under-
lying biology of the HF syndrome. These biomarkers
now have the highest level of recommendation in the
most recent ACC/AHA guidelines for both the diag-
nosis of patients with uncertain symptoms, and for
establishing prognosis in patients with established
HF. However, clinicians need to appreciate the com-
plex dynamics of natriuretic peptide levels, taking
patient characteristics, comorbidities, and other
therapies into account as they use and interpret these
biomarkers. Ongoing studies on the use of natriuretic
peptide measurements may help us to individualize
our treatment plans above and beyond guideline
recommendations.
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